On the other hand, the results of placebo-controlled non-inferiority randomized clinical trials suggested that DPP-4 inhibitors have a neutral effect of cardiovascular events in patients with type 2 diabetes [7–9]. Here, DPP4 is linked to type 2 diabetes mellitus.